Position paper on therapeutic drug monitoring of antiretroviral agents

AIDS Research and Human Retroviruses

Volumn 18, Issue 12, 2002, Pages 825-834

  Acosta, Edward P ^a   Gerber, John G ^b   Morse, Gene ^c   Aberg, Judith ^d   Aweeka, Francesca ^e   Berry, Melissa ^f   Blaschke, Terrence ^g   Brundage, Richard ^h   Christensen, Rolf ⁱ   Fletcher, Courtney V ^b   Flexner, Charles ^j   Haas, David ^k   Hall, Stephen ^l   Hamzeh, Fayez ^j   Haubrich, Richard ^m   Kashuba, Angela ⁿ   Katzenstein, David ^g   Lawrence, Jody ^e   Lertora, Juan ^o   Para, Michael ^p   Rosenkranz, Susan ^q   Sheiner, Lewis ^e   Wilkinson, Grant ^k   Wood, Alastair J J ^k   Wu, Hulin ^q   more..

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d WASHINGTON UNIVERSITY   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f MD Operations Center   (United States)

^g STANFORD UNIVERSITY   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

ⁱ UNIVERSITY OF WASHINGTON   (United States)

^j JOHNS HOPKINS HOSPITAL   (United States)

^k VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^l INDIANA UNIVERSITY   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF NORTH CAROLINA   (United States)

^o TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^p OHIO STATE UNIVERSITY   (United States)

^q HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPRENAVIR; ANTIRETROVIRUS AGENT; EFAVIRENZ; INDINAVIR; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; ZIDOVUDINE;

ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG MONITORING; DRUG SELF ADMINISTRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; SAMPLING; STANDARDIZATION;

ANTI-HIV AGENTS; DRUG MONITORING; EVIDENCE-BASED MEDICINE; HIV INFECTIONS; HUMANS;

EID: 0036376785     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/08892220260190290     Document Type: Article

References (33)

1. Pharmacodynamics of HIV-1 protease inhibitors
2. Indinavir concentrations and antiviral effect
3. Pharmacokinetic (PK) evaluation of nelfinavir (NFV) in combination with nevirapine (NVP) or ritonavir (RTV) in HIV-infected children - PACTG 403
4. + T-cell counts in HIV-infected patients
5. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease
6. Efavirenz plasma levels can predict treatment failure and central nervous system side effect in HIV-1-infected patients
7. Ordered accumulation of mutations in HIV protease confers resistance to ritonavir
8. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects
9. A 24-week open-label phase I/II evaluation of the HIV protease inhibitor MK-639 (indinavir)
10. A pilot study of nevirapine, indinavir, and lamivudine among patients with advanced human immunodeficiency virus disease who have had failure of combination nucleoside therapy
11. Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons with human immunodeficiency virus type 1
12. Low plasma levels of indinavir (IDV) are highly predictive of virological treatment failure in patinets using IDV-containing triple therapy
13. Virologic response-plasma concentration relationship in phase III study of nelfinavir mesylate
14. Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir and saquinavir
15. Pharmacokinetic and pharmacodynamic study of the human immunodeficiency virus protease inhibitor amprenavir after multiple oral dosing
16. Importance of protease inhibitor plasma levels in HIV-infected patients treated with genotypic-guided therapy: Pharmacological data from the Viradapt study
17. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients
18. Pharmacologic characteristics of efavirenz and nelfinavir associated with virologic response in HIV-infected children
19. Concentration-controlled zidovudine therapy
20. Therapeutic drug monitoring of nelfinavir 1250 mg bid in treatment naive patients improves therapeutic outcome after 1 year: Results from ATHENA
21. Usefulness of protease inhibitor therapeutic drug monitoring? PharmAdapt: A prospective multicentric randomized controlled trial: 12 Week results
22. Long term efficacy of protease inhibitor plasma drug level monitoring (PI TDM): PharmAdapt w 32 results
23. Concentration-controlled compared with conventional antiretroviral therapy for human immunodeficiency virus infection
24. Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus
25. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy
26. 1-acid glycoprotein concentration on the antiviral efficacy of human immunodeficiency virus protease inhibitors
27. A preliminary evaluation of nelfinavir mesylate, an inhibitor of human immunodeficiency virus (HIV)-1 protease, to treat HIV infection
28. Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy
29. A randomized, double-blind trial comparing combinations of nevirapine, didanosine, and zidovudine for HIV infected patients
30. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals